New Classes of Therapy in Multiple Myeloma

Slides:

Advertisements

Similar presentations

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Advertisements

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Myeloma hope new treatment in the horizon

R1.이용석 / modulator pf.한재준.

ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM

MOnoclonal antibodies and potential applications in migraine

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Pieter Sonneveld,

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Metastatic HER2+ Breast Cancer: Resistance

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Treatment Algorithms in Melanoma: Past, Present, and Future

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Advanced NSCLC Without Actionable Mutations

Current and Emerging Treatments for IBD

State of the Art in HCC: Immune Checkpoint Modulation

Discussion Outline Cells of the Immune System.

Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

Metastatic Renal Cell Carcinoma

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( ) Sundar Jagannath, Rafat Abonour, Brian.

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

The Evolving Role of Immunotherapy in NSCLC

Basics of Immunotherapy Potential Therapeutic Targets.

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Next-Gen Psoriasis Therapies:

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Advances in Multiple Myeloma

Evaluating Next-Generation BTK Inhibitors

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Targeting BTK Signaling in B-Cell Malignancies

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Activity Goals Program Overview.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Staying Abreast of Best Practices Across the Clinical Continuum

Getting to Grips With the Science of CGRP and Migraine

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Non-Chemotherapy Combinations in CLL

The Changing Field of Melanoma: Ipilimumab.

Evaluating BTK Inhibitors in CLL

Oral Prostacyclin Pathway Agents in PAH

FDA-Approved PI3K Inhibitors for CLL and FL

Proteasome Inhibitors and Patients

On the Cusp: New Approaches for Multiple Myeloma

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Third-Generation EGFR TKIs

CDK4/6 Inhibitors.

Targeting Apoptosis in AML

PAH Pathways: What Do the Data Tell Us?”

Spotlight on Monoclonal Antibodies in Multiple Myeloma

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Challenges and Emerging Solutions in Anemia Management Explored

Maintenance therapies in Multiple Myeloma

Presentation transcript:

New Classes of Therapy in Multiple Myeloma

Learning Goals

Overall Survival in MM

Backbone Agents

MM Agents Approved in 2015

Continuing Challenges

Therapies in Development

Targeting the Proteasome

TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

TOURMALINE-MM1 Efficacy

Oprozomib

HDAC Inhibitors Targeting the Aggresome Pathway

PANORAMA-1 Efficacy

PANORAMA-1 Toxicity

Future Directions for HDAC Inhibitors

Potential mAb Targets

Elotuzumab

ELOQUENT-2 Len/Dex ± Elotuzumab

Len/Dex ± Elotuzumab Additional Insights

Daratumumab Potential Mechanisms of Action

Daratumumab Monotherapy Phase 2, ≥ 3 Lines of Prior Therapy

Daratumumab in Combination

Therapies in Development Antibodies

Pembrolizumab + Pom/Dex

Therapies in Development Novel Targets

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)